Oligonucleotide-based active pharmaceutical ingredients (APIs) have emerged as a powerful approach to treating diseases. With hundreds of them in advanced clinical trials, a potential metric ton demand for certain products is expected that might not be easily fulfilled by conventional solid phase oligonucleotide synthesis (SPOS). It is essential to develop more efficient, more sustainable, and highly scalable manufacturing techniques. This whitepaper explains how the innovative stirred-bed technology (SBT) for SPOS fulfills all these requirements and represents an economical engineering solution with a simple reactor design and adapted chemistry. Thus, ton-scale commercial oligonucleotide API manufacture with unmatched process mass intensity is within reach.

Read more about manufacturing oligonucleotides with stirred-bed technology in our white paper.